Dengue Vaccine: Balancing Benefit and Potential Risk

During year 3 after vaccination, risk for dengue-related hospitalization — although decreased overall in vaccinees aged 2 to 16 years — was increased in those aged <9.

Waning immunity after vaccination potentially predisposes vaccinees to more-severe disease during infection with a new serotype, so long-term follow-up is essential. Investigators now present pooled efficacy data for year 3 of two phase III trials — and years 3 and 4 of one phase IIB trial — of CYD-TDV, a recombinant, live, attenuated tetravalent dengue vaccine (NEJM JW Infect Dis Dec 2014 and N Engl J Med 2015; 372:113). These industry-funded trials included >35,000 children aged 2 to 16 years in Asian-Pacific and Latin American countries; vaccine was administered in three doses (at 0, 6, and 12 months).

Although the relative risk for dengue-related hospitalization was 0.84 overall, it was 1.58 among those aged <9. Vaccine efficacy was high…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Dengue Vaccine: Balancing Benefit and Potential Risk

Topics

Reviewing Author